Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
GammaDelta Therapeutics Ltd
GammaDelta Therapeutics Ltd
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Takeda Pharmaceutical to acquire GammaDelta Therapeutics
Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Regulatory
FDA grants IND clearance to GammaDelta cancer therapy
The FDA also granted orphan drug designation to allogeneic Vδ1 γδ T cell therapy (GDX012) for the treatment of Acute Myeloid Leukaemia (AML)
Research & Development
GammaDelta announces publication of new data in Nature Immunology
Findings support the development of gamma delta T cells for gastrointestinal diseases
Pharmaceutical
GammaDelta Therapeutics appoints CMO
Research & Development
Collaboration to advance tissue-derived gamma delta T Cells
Global R&D company Takeda collaborates with GammaDelta, developers of immunotherapies for cancer and other serious diseases
Research & Development
GammaDelta Therapeutics expands management team
Paolo Paoletti leads as Chief Executive Officer
Subscribe now